search
Back to results

Distal Renal Denervation

Primary Purpose

Hypertension, Resistant to Conventional Therapy

Status
Completed
Phase
Not Applicable
Locations
Russian Federation
Study Type
Interventional
Intervention
Distal renal denervation
Conventional renal denervation
Sponsored by
Tomsk National Research Medical Center of the Russian Academy of Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension, Resistant to Conventional Therapy focused on measuring Hypertension, Catheter Ablation, Renal Nerves

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • systolic BP is equal or greater than 160 mmHg or diastolic BP is equal or greater than 100 mmHg,
  • stable (>3 months) treatment with full doses of at least 3 antihypertensive drugs including a diuretic,
  • given written informed consent

Exclusion Criteria:

  • secondary hypertension
  • 24h-mean systolic BP <135 mmHg,
  • estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2,
  • extended disease of renal artery,
  • any other clinically important disorders/comorbidities significantly increasing risk of endovascular intervention (investigator's assessment)

Sites / Locations

  • Tomsk National Research Medical Center of the Russian Academy of Sciences

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Distal renal denervation

Conventional renal denervation

Arm Description

Endovascular denervation of segmental branches of renal artery

Endovascular denervation of main trunk of renal artery

Outcomes

Primary Outcome Measures

Changes of 24h-mean Systolic BP Assessed by Ambulatory Blood Pressure Monitoring (ABPM)

Secondary Outcome Measures

Number of Adverse Events
Number of Adverse Events
Changes of Arterial Resistance Index Measured by Doppler Flowmetry in the Right Segmental Renal Arteries
Resistance index is calculated as the relative difference between a peak systolic and end diastolic blood flow velocities assessed by ultrasound Doppler flowmetry
Changes of Arterial Resistance Index Measured by Doppler Flowmetry in the Left Segmental Renal Arteries
Resistance index calculated as the relative difference between a peak systolic and end diastolic blood flow velocities assessed by ultrasound Doppler flowmetry
Changes of Serum Creatinine
Changes of Serum Creatinine
Changes of Estimated Glomerular Filtration Rate (eGFR)
Changes of Estimated Glomerular Filtration Rate (eGFR)
Changes of 24h-mean Diastolic BP
Changes of 24h-mean Systolic BP
Changes of 24h-mean Diastolic BP
Changes of Office Systolic BP
Changes of Office Systolic BP
Changes of Office Diastolic BP
Changes of Office Diastolic BP
Changes of Daytime Systolic BP
Changes of Daytime Mean Systolic BP
Changes of Daytime Mean Diastolic BP
Changes of Daytime Mean Diastolic BP
Changes of Nighttime Mean Systolic BP
Changes of Nighttime Mean Systolic BP
Changes of Nighttime Mean Diastolic BP
Changes of Nighttime Mean Diastolic BP

Full Information

First Posted
January 26, 2016
Last Updated
October 4, 2021
Sponsor
Tomsk National Research Medical Center of the Russian Academy of Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT02667912
Brief Title
Distal Renal Denervation
Official Title
Anatomically Optimized Distal Renal Denervation for Treatment of Resistant Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
October 2021
Overall Recruitment Status
Completed
Study Start Date
January 2013 (undefined)
Primary Completion Date
July 2016 (Actual)
Study Completion Date
December 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Tomsk National Research Medical Center of the Russian Academy of Sciences

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Objective of this study is to evaluate whether a distal mode of endovascular renal denervation with the treatment performed primarily in segmental branches of renal artery is more effective than conventional mode of the intervention with the treatment equally distributed within its main trunk for the treatment of drug-resistant hypertension.
Detailed Description
Recent spectacular failure of renal denervation (RDN) therapy in SymplicityHTN-3 trial in fact might be easily predicted from the very beginning. Conventional RDN done as 4-6 point treatments equally distributed within main trunk of renal artery (RA) may only be effective if renal plexus tightly surrounds the artery throughout its whole course with equal longitudinal and circumferential density of the nerve fibers. While this idea itself is unnaturally idealistic also a number of surgical studies demonstrated that proximally majority of renal nerves go at a distance from RA obliquely to its course and join the artery mainly in its distal part (fan-shaped renal plexus with wide base directed toward aorta and apex converging to renal gate). We developed a distal mode of RDN targeting segmental branches of RA and conducted a single-center double-blind randomized controlled parallel group study to compare its efficacy and safety to those of conventional RDN in patients with drug-resistant hypertension.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Resistant to Conventional Therapy
Keywords
Hypertension, Catheter Ablation, Renal Nerves

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
55 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Distal renal denervation
Arm Type
Experimental
Arm Description
Endovascular denervation of segmental branches of renal artery
Arm Title
Conventional renal denervation
Arm Type
Active Comparator
Arm Description
Endovascular denervation of main trunk of renal artery
Intervention Type
Procedure
Intervention Name(s)
Distal renal denervation
Intervention Description
Percutaneous endovascular intervention when catheter-based electrode (Symplicity Flex; Medtronic, Inc.) is used for stepwise radiofrequency energy delivery to segmental branches of the renal artery in a number of points distributed along the length and circumference of the vessels in order to ablate renal nerve plexus
Intervention Type
Procedure
Intervention Name(s)
Conventional renal denervation
Intervention Description
Percutaneous endovascular intervention when catheter-based electrode (Symplicity Flex; Medtronic, Inc.) is used for stepwise radiofrequency energy delivery to the main trunk of the renal artery in a number of points equally distributed along its length and circumference in order to ablate renal nerve plexus
Primary Outcome Measure Information:
Title
Changes of 24h-mean Systolic BP Assessed by Ambulatory Blood Pressure Monitoring (ABPM)
Time Frame
From baseline to 6 months
Secondary Outcome Measure Information:
Title
Number of Adverse Events
Time Frame
From baseline to 6 months
Title
Number of Adverse Events
Time Frame
From baseline to 12 months
Title
Changes of Arterial Resistance Index Measured by Doppler Flowmetry in the Right Segmental Renal Arteries
Description
Resistance index is calculated as the relative difference between a peak systolic and end diastolic blood flow velocities assessed by ultrasound Doppler flowmetry
Time Frame
From baseline to 6 months
Title
Changes of Arterial Resistance Index Measured by Doppler Flowmetry in the Left Segmental Renal Arteries
Description
Resistance index calculated as the relative difference between a peak systolic and end diastolic blood flow velocities assessed by ultrasound Doppler flowmetry
Time Frame
From baseline to 6 months
Title
Changes of Serum Creatinine
Time Frame
From baseline to 6 months
Title
Changes of Serum Creatinine
Time Frame
From baseline to 12 months
Title
Changes of Estimated Glomerular Filtration Rate (eGFR)
Time Frame
From baseline to 6 months
Title
Changes of Estimated Glomerular Filtration Rate (eGFR)
Time Frame
From baseline to 12 months
Title
Changes of 24h-mean Diastolic BP
Time Frame
From baseline to 6 months
Title
Changes of 24h-mean Systolic BP
Time Frame
From baseline to 12 months
Title
Changes of 24h-mean Diastolic BP
Time Frame
From baseline to 12 months
Title
Changes of Office Systolic BP
Time Frame
From baseline to 6 months
Title
Changes of Office Systolic BP
Time Frame
From baseline to 12 months
Title
Changes of Office Diastolic BP
Time Frame
From baseline to 6 months
Title
Changes of Office Diastolic BP
Time Frame
From baseline to 12 months
Title
Changes of Daytime Systolic BP
Time Frame
From baseline to 6 months
Title
Changes of Daytime Mean Systolic BP
Time Frame
From baseline to 12 months
Title
Changes of Daytime Mean Diastolic BP
Time Frame
From baseline to 6 months
Title
Changes of Daytime Mean Diastolic BP
Time Frame
From baseline to 12 months
Title
Changes of Nighttime Mean Systolic BP
Time Frame
From baseline to 6 months
Title
Changes of Nighttime Mean Systolic BP
Time Frame
From baseline to 12 months
Title
Changes of Nighttime Mean Diastolic BP
Time Frame
From baseline to 6 months
Title
Changes of Nighttime Mean Diastolic BP
Time Frame
From baseline to 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: systolic BP is equal or greater than 160 mmHg or diastolic BP is equal or greater than 100 mmHg, stable (>3 months) treatment with full doses of at least 3 antihypertensive drugs including a diuretic, given written informed consent Exclusion Criteria: secondary hypertension 24h-mean systolic BP <135 mmHg, estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2, extended disease of renal artery, any other clinically important disorders/comorbidities significantly increasing risk of endovascular intervention (investigator's assessment)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stanislav Pekarskiy, MD, PhD
Organizational Affiliation
Tomsk National Research Medical Center of the Russian Academy of Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
Tomsk National Research Medical Center of the Russian Academy of Sciences
City
Tomsk
ZIP/Postal Code
634009
Country
Russian Federation

12. IPD Sharing Statement

Citations:
PubMed Identifier
28005705
Citation
Pekarskiy SE, Baev AE, Mordovin VF, Semke GV, Ripp TM, Falkovskaya AU, Lichikaki VA, Sitkova ES, Zubanova IV, Popov SV. Denervation of the distal renal arterial branches vs. conventional main renal artery treatment: a randomized controlled trial for treatment of resistant hypertension. J Hypertens. 2017 Feb;35(2):369-375. doi: 10.1097/HJH.0000000000001160.
Results Reference
result
PubMed Identifier
34806762
Citation
Pisano A, Iannone LF, Leo A, Russo E, Coppolino G, Bolignano D. Renal denervation for resistant hypertension. Cochrane Database Syst Rev. 2021 Nov 22;11(11):CD011499. doi: 10.1002/14651858.CD011499.pub3.
Results Reference
derived

Learn more about this trial

Distal Renal Denervation

We'll reach out to this number within 24 hrs